Eli Lilly and Company (LLY) Competitors $833.08 -22.28 (-2.60%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$830.55 -2.53 (-0.30%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LLY vs. AMGN, BIIB, INCY, MRNA, VKTX, VRTX, ABBV, JNJ, MRK, and PFEShould you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Amgen (AMGN), Biogen (BIIB), Incyte (INCY), Moderna (MRNA), Viking Therapeutics (VKTX), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector. Eli Lilly and Company vs. Its Competitors Amgen Biogen Incyte Moderna Viking Therapeutics Vertex Pharmaceuticals AbbVie Johnson & Johnson Merck & Co., Inc. Pfizer Amgen (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Do analysts prefer AMGN or LLY? Amgen currently has a consensus price target of $309.42, indicating a potential upside of 6.65%. Eli Lilly and Company has a consensus price target of $948.56, indicating a potential upside of 13.86%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 1 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35Eli Lilly and Company 0 Sell rating(s) 10 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.64 Which has more volatility and risk, AMGN or LLY? Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Is AMGN or LLY more profitable? Eli Lilly and Company has a net margin of 25.91% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Eli Lilly and Company's return on equity.Company Net Margins Return on Equity Return on Assets Amgen18.96% 174.71% 13.12% Eli Lilly and Company 25.91%92.72%16.89% Does the media refer more to AMGN or LLY? In the previous week, Eli Lilly and Company had 98 more articles in the media than Amgen. MarketBeat recorded 158 mentions for Eli Lilly and Company and 60 mentions for Amgen. Eli Lilly and Company's average media sentiment score of 1.21 beat Amgen's score of 1.14 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 40 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Eli Lilly and Company 112 Very Positive mention(s) 22 Positive mention(s) 18 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Which has preferable earnings & valuation, AMGN or LLY? Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.67$4.09B$12.2323.72Eli Lilly and Company$45.04B17.50$10.59B$15.3054.45 Do institutionals and insiders believe in AMGN or LLY? 76.5% of Amgen shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.8% of Amgen shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is AMGN or LLY a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.7%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 39.2% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. SummaryEli Lilly and Company beats Amgen on 15 of the 20 factors compared between the two stocks. Get Eli Lilly and Company News Delivered to You Automatically Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LLY vs. The Competition Export to ExcelMetricEli Lilly and CompanyLarge Cap Pharma IndustryMedical SectorNYSE ExchangeMarket Cap$809.55B$274.61B$6.10B$21.91BDividend Yield0.70%2.56%5.67%3.61%P/E Ratio54.4531.3385.2728.85Price / Sales17.505.23612.7883.44Price / Cash60.0914.7838.5024.17Price / Book55.4319.9012.724.51Net Income$10.59B$8.49B$3.30B$1.01B7 Day Performance-0.88%-2.74%0.90%-3.46%1 Month Performance10.22%2.17%6.30%-1.86%1 Year Performance-10.62%-4.36%80.41%10.34% Eli Lilly and Company Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LLYEli Lilly and Company4.9971 of 5 stars$833.08-2.6%$948.56+13.9%-8.5%$809.55B$45.04B54.4547,000Trending NewsAnalyst ForecastAMGNAmgen4.5598 of 5 stars$294.12-1.3%$309.70+5.3%-9.6%$158.52B$33.42B24.0828,000Positive NewsAnalyst UpgradeAnalyst RevisionBIIBBiogen4.616 of 5 stars$153.72-3.9%$180.04+17.1%-22.3%$22.58B$9.68B14.737,605Trending NewsAnalyst ForecastAnalyst RevisionINCYIncyte4.3772 of 5 stars$87.42+0.7%$83.64-4.3%+28.2%$17.08B$4.24B19.872,617Analyst ForecastMRNAModerna4.2436 of 5 stars$28.15-1.2%$41.81+48.5%-52.8%$10.93B$3.24B-3.735,800Analyst ForecastVKTXViking Therapeutics3.9302 of 5 stars$31.92+7.4%$86.42+170.7%-46.3%$3.58BN/A-20.8420Analyst ForecastGap UpVRTXVertex Pharmaceuticals4.7915 of 5 stars$401.40-0.5%$493.81+23.0%-14.4%$102.97B$11.02B28.716,100Positive NewsAnalyst ForecastAnalyst RevisionABBVAbbVie4.5822 of 5 stars$228.88-2.2%$228.22-0.3%+18.8%$404.68B$56.33B109.0955,000Positive NewsAnalyst ForecastJNJJohnson & Johnson4.6662 of 5 stars$188.19-0.2%$189.12+0.5%+18.8%$453.40B$90.63B20.13138,100Trending NewsUpcoming EarningsAnalyst ForecastMRKMerck & Co., Inc.4.9928 of 5 stars$88.98-0.2%$106.41+19.6%-21.4%$222.43B$64.17B13.7275,000Trending NewsAnalyst ForecastAnalyst RevisionPFEPfizer4.9554 of 5 stars$26.98-1.4%$28.41+5.3%-15.5%$153.31B$63.83B14.3481,000Trending NewsDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Amgen Competitors Biogen Competitors Incyte Competitors Moderna Competitors Viking Therapeutics Competitors Vertex Pharmaceuticals Competitors AbbVie Competitors Johnson & Johnson Competitors Merck & Co., Inc. Competitors Pfizer Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:LLY) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eli Lilly and Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Eli Lilly and Company With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
